Novo Nordisk, Chip Ganassi Racing Teams and Charlie Kimball Honor the Diabetes Community With the No. 42 Tresiba® (insulin degludec injection 200 Units/mL)
Indianapolis, Ind. (May 16, 2016) – Chip Ganassi Racing Teams (CGRT) and longtime partner Novo Nordisk, a world leader in diabetes care, along with their Verizon IndyCar Series driver Charlie Kimball, will join together to honor the diabetes community at the 100th running of the Indianapolis 500.
Novo Nordisk Chip Ganassi Racing will change the number of Kimball’s Tresiba® Chevrolet from its usual No. 83 to No. 42 at the 2016 Indianapolis 500. He will borrow the number from fellow CGRT teammate, Kyle Larson, driver of the No. 42 Target Chevrolet SS in the NASCAR Sprint Cup Series (NSCS). Larson has a cousin living with diabetes, so the program has a personal tie for him. Larson’s No. 42 NSCS car will carry Kimball’s name on it for the Coca-Cola 600 race weekend, also running on May 29, to honor those living with diabetes.
The number 42 is a reference to the duration of action of Tresiba®, a once-daily, long-acting basal insulin approved for blood sugar control in adults with diabetes, which was launched by Novo Nordisk earlier this year. Tresiba® lasts at least 42 hours after eight once-daily injections (0.4 U/kg). Patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Patients must ensure that at least eight hours have elapsed between Tresiba®injections.
Kimball was diagnosed with type 1 diabetes in 2007, and in addition to sporting the logo on his car, takes Tresiba®, along with a mealtime insulin, as part of his daily diabetes management.
As part of the efforts to raise diabetes awareness at the Indianapolis 500, Kimball’s No. 42 Tresiba® Chevrolet will carry the name of 42 leaders in the diabetes community. Included among the names on the car are Dominique Wilkins, Billie Jean King, diabetes organizations such as JDRF, and first all-diabetes professional cycling team, Team Novo Nordisk. Additionally, Novo Nordisk will make a $4,200 donation to the Indiana Chapter of the American Diabetes Association (ADA) on behalf of the Verizon IndyCar Series driver who is leading the race after the 42nd lap of the Indianapolis 500. Novo Nordisk will also make the same $4,200 donation to the Charlotte Chapter of the ADA on behalf of the NSCS driver who leads the Coke 600 after lap 42.
The 2016 race season marks the eighth consecutive year of partnership between Novo Nordisk and Kimball and the sixth year of partnership between Kimball, Novo Nordisk and CGRT. Since his type 1 diabetes diagnosis, Kimball has been a passionate diabetes advocate. He is the face of Novo Nordisk’s award-winning Race with Insulin® campaign, which aims to raise awareness and educate the public about diabetes management.
For the remainder of the 2016 Verizon IndyCar Series campaign, Kimball will run his normal car number, No. 83.
Charlie Kimball, No. 42 Tresiba® Chevrolet (Verizon IndyCar Series)
“The 100th running of the Indianapolis 500 will be the highlight of this year’s season and it gives me a great opportunity to honor the diabetes community and help inspire those people living with or affected by diabetes. As a race car driver and a person living with diabetes, the duration of action of Tresiba® is important to me and plays an important role in my management plan. I am honored to represent Novo Nordisk and Chip Ganassi Racing and to share my story with the diabetes community.”
Kyle Larson, No. 42 Target Chevrolet (NSCS)
“All of us who race for Chip (Ganassi) really are one team and it’s really cool to share the No. 42 with Charlie, especially for this historic race. He is a strong and popular advocate for the diabetes community and I can’t wait to see him and the No. 42 in this year’s Indianapolis 500.”
Chip Ganassi, Team Owner, Chip Ganassi Racing Teams
“It’s been great to see Novo Nordisk use their racing partnership with Chip Ganassi Racing Teams to launch one of their brands, and I love that we’re strengthening our ‘one team’ mantra with the sharing of the number 42 across different series. The number 83 is obviously very meaningful to both Charlie and myself, but the number 42 is also just as meaningful with this product and the diabetes community. Charlie had a great run last year at the 500, so hopefully the 42 will bring Novo Nordisk Chip Ganassi Racing and Charlie their first Indianapolis 500 victory.”
Camille Lee, Senior Vice President, Diabetes & Obesity Marketing, Novo Nordisk Inc.
“As an individual living with diabetes, Charlie continues to be such an inspiration and leader for the community of others affected by diabetes. By changing the number of the Tresiba® Chevrolet to 42, and displaying names of real people touched by the disease on his car for this historic race, he is making great strides to honor the diabetes community.”
What is Tresiba®?
- Prescription Tresiba® is a long-acting insulin used to control high blood sugar in adults with diabetes
- Tresiba® is not for people with diabetic ketoacidosis
- Tresiba® is available in 2 concentrations: 200 units/mL and 100 units/mL
- It is not known if Tresiba® is safe and effective in children under 18 years of age